南非多替拉韦方案启动后早期血清肌酐变化的影响因素
本研究为ADVANCE随机对照试验的二次分析,纳入689例起始多替拉韦联合恩曲他滨及TDF或TAF方案者,第4周血清肌酐平均变化11.3(SD 9.9)μmol·L⁻¹;多替拉韦AUC、TDF使用、男性、基线肌酐及UGT1A1 rs929596多态性与变化相关。
要点
- 多替拉韦AUC升高与第4周血清肌酐上升相关(β=2.78 μmol·L⁻¹)。
- TDF使用及男性与早期血清肌酐升高相关,需关注肾功能监测。
- UGT1A1 rs929596关联经多重检验校正后不显著,遗传因素待验证。
核心结论
- 多替拉韦方案启动后早期血清肌酐变化与临床及药代动力学多因素相关。
- UGT1A1多态性可能起作用,但需进一步研究遗传决定因素。
研究设计与样本
- ADVANCE随机对照试验(NCT03122262)数据的二次分析。
- 纳入689例,其中470例有药代动力学数据、315例有遗传数据。
- 采用线性回归模型,校正年龄、性别、基线肌酐、HIV-1 RNA、CD4计数、体重及复方磺胺甲噁唑使用。
主要发现
- 第4周血清肌酐平均变化为11.3(SD 9.9)μmol·L⁻¹。
- 多替拉韦24小时AUC对数升高:β=2.78 μmol·L⁻¹(95%CI 0.54, 5.01)。
- TDF使用:β=2.30(95%CI 0.53, 4.06);男性:β=5.20(95%CI 2.92, 7.48)。
- 基线血清肌酐:β=-0.22(95%CI -0.31, -0.12)。
- UGT1A1 rs929596 A→G显性模型:β=-2.33(95%CI -4.49, -0.17),未通过多重检验校正。
临床怎么用
- 启动多替拉韦方案后应关注早期血清肌酐变化,尤其联用TDF及男性患者。
- 多替拉韦暴露较高者可能肌酐上升更明显,提示关注药代动力学差异。
- 遗传检测尚无足够证据用于常规预测肌酐变化。
局限性
- 为随机对照试验的二次分析,部分参与者缺乏药代动力学或遗传数据。
- UGT1A1关联未通过多重检验校正,遗传结论有限。
- 研究人群为南部非洲队列,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Dolutegravir increases serum creatinine by inhibiting its renal tubular secretion and elimination. We investigated determinants of early changes in serum creatinine in a southern African cohort starting first-line dolutegravir-based antiretroviral therapy (ART). METHODS: We conducted a secondary analysis of data from participants in a randomized controlled trial of dolutegravir, emtricitabine and tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF) (ADVANCE, NCT03122262). We assessed clinical, pharmacokinetic and genetic factors associated with change in serum creatinine from baseline to Week 4 using linear regression models adjusted for age, sex, baseline serum creatinine, HIV-1 RNA concentration, CD4 T-cell count, total body weight and co-trimoxazole use. RESULTS: We included 689 participants, of whom 470 had pharmacokinetic data and 315 had genetic data. Mean change in serum creatinine was 11.3 (SD 9.9) μmol.L-1. Factors that were positively associated with change in serum creatinine at Week 4 were increased log dolutegravir area under the 24-h concentration-time curve (change in creatinine coefficient [β] = 2.78 μmol.L-1 [95% confidence interval (CI) 0.54, 5.01]), TDF use (β = 2.30 [0.53, 4.06]), male sex (β = 5.20 [2.92, 7.48]), baseline serum creatinine (β = -0.22 [-0.31, -0.12]) and UGT1A1 rs929596 A→G polymorphism with a dominant model (β = -2.33 [-4.49, -0.17]). The latter did not withstand correction for multiple testing. CONCLUSIONS: Multiple clinical and pharmacokinetic factors were associated with early change in serum creatinine in individuals initiating dolutegravir-based ART. UGT1A1 polymorphisms may play a role, but further research on genetic determinants is needed.
引用
- Mpofu R, Kawuma AN, Wasmann RE, et al. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024. PMID: 38332460. doi:10.1111/bcp.16009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。